GF/B38/EDPo5: Decision on the Secretariat's Recommendation on Grant Extensions¹

Approval Date - 13th December 2017

1.2 Set forth below is the Secretariat's recommendation to approve grant extensions.

The Board:

- 1. Approves the extension budget and revised implementation period recommended for each grant listed in Table 2 of GF/B38/ER05 ("Table 2");
- 2. Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding.

This decision does not have material budgetary implications for operating expenses.

Table 2: Secretariat's Recommendation on Grant Extensions

Please note: Each country name is linked to the extranet site where supporting documents are available for review

N	Applicant	Disease Compone nt	Grant Name	Currency	Total Extension Budget ²	Additional Fundings	Previous Extensions Granted (Cumulative Months)	Proposed Extension Duration (Months)	Grant End Date
1	<u>Nigeri</u> a	HIV	NGA-H-NACA	USD	29,558,618	29,558,618	0	18	30/06/2019
2		HIV	NGA-H-FHI360	USD	88,453,561	88,453,561	0	18	30/06/2019
3		ТВ	NGA-T-IHVN	USD	28,005,164	8,016,145	0	18	30/06/2019
4		TB	NGA-T-ARFH	USD	20,937,632	0	0	18	30/06/2019

¹ Nigeria HIV, Nigeria TB with total incremental funding of US\$ 118,012,179 for HIV and US\$ 48,942,796 for TB.

² In accordance with the Comprehensive Funding Policy (GF/B36/O2 – Annex 1, Rev 1), where the extension is for a grant for a disease component with a 2017-19 allocation, the Total Extension Budget will be funded from the 2017-2019 allocation.

³ Additional funding is calculated as the Total Extension Budget net of forecasted funds remaining in the grant, and may vary according to the final reconciliation of remaining funds, up to a maximum of the Total Extension Budget. The Total Extension Budget will remain the same.